ophthalmic surgery
Conditions
Interventions
Trade Name: atropine
Product Name: atropine
Pharmaceutical Form: Solution for injection/infusion
INN or Proposed INN: 682487
CAS Number: 51-55-8
Other descriptive name: METHYLATROPINE NITRATE
Concentr
Sponsors
UMCG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients scheduled to undergo elective ophthalmic surgery under general anesthesia. Patients must be 18 years or older. No selection will be made regarding gender, age, ASA-classification, co-morbidity or ethnic background. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0
Exclusion criteria
Exclusion criteria: - Patient’s refusal - Patient’s age < 18 years - Patients in which atropine is contra-indicated, such as severe aortic valve stenosis, hypertrophic cardiomyopathy or coronary artery disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Timepoint(s) of evaluation of this end point: during induction;Main Objective: The evolution of the different hemodynamic variables compared to their respective baseline value. Most attention will be drawn to the evolution of the heart rate en arterial blood pressure, the cardiac output, the peripheral tissue oxygenation (thenar) and cerebral oxygen saturation (forehead) and buccal microcirculation;Secondary Objective: The requirement of other vasoactive medication (norepinephrine) for hemodynamic control in either group. The evolution of systemic vascular resistance. ;Primary end point(s): The evolution of the different hemodynamic variables compared to their respective baseline value. Most attention will be drawn to the evolution of the heart rate en arterial blood pressure, the cardiac output, the peripheral tissue oxygenation (thenar) and cerebral oxygen saturation (forehead) and buccal microcirculation | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): The requirement of other vasoactive medication (norepinephrine) for hemodynamic control in either group. The evolution of systemic vascular resistance. ;Timepoint(s) of evaluation of this end point: during induction | — |
Countries
Netherlands
Contacts
Public Contactkalmar
umcg
Outcome results
None listed